The potential prognostic value of PD1 expression in tumor-infiltrated lymphocytes (TILS) was also evaluated, but no correlation with clinical outcomes was achieved, even when this biomarker was combined with PD-L1 expression on the tumor. The gene discussed is PDCD1; the disease is neoplasm.